Dr Sylwia Ammoun
Profiles

Dr Sylwia Ammoun

Senior Research Fellow

Biomedical Research - Institute of Translational & Stratified Medicine (Faculty of Medicine and Dentistry)

Qualifications

EDUCATION AND QUALIFICATIONS

2005

PhD dissertation, Uppsala University, Sweden, Orexin Receptors in Recombinant CHO Cells. Signaling to Short- and Long Term Cells responses

2004

Transfer, Uppsala University, Sweden

1997

Degree of Master of Science, Uppsala University, Sweden Immunomodulatory-and-cytokine gene-cancer therapy

1996

BScs, Uppsala University, Sweden

 

Professional membership

Member of South of England Brain Tumour Alliance (SEBTA)

Teaching interests

TEACHING EXPERIENCE

I enjoy sharing myknowledge and always appreciate teaching in which I have 18 years of experience.

Uppsala University, Sweden  

From 1998 to 2005 I taughtmedical-, pharmacology- and nurse-students in the following subjects:hemodynamics (blood-vascular circulation-system), safety of medical equipment(current), optical refraction of the eye, heart anatomy (dissection), oscilloscopeand pacemaker and muscle structure and function. During this time I alsosupervised undergraduate and BSc biomedical students and lab assistants.

Plymouth University Peninsula Schools of Medicine and Dentistry,Plymouth, UK

From 2006 until present Ihave supervised PhD, BSc and undergraduate students indifferent projects.Between 2006 and 2007 I taught medical students in 'Neurodegenerativedisorders' and 'Disease prevention and management-vaccines ‘and 2019 biomedicalstudents in 'Tumours of the nervous system'.

TEACHING EDUCATION

2014     Internaland External Doctoral Examiners training

2011     Learningand Teaching for general Teaching Associates (GTA) training including: Theoriesof Learning and Teaching, Planning Sessions and Delivering Presentations,Learning in Groups, Evaluating Teaching and Giving Feedback, Assessment,Dealing with difficult Situations and Assessment Criteria and Marketing.

2008     Problem-basedlearning (PBL) facilitator training.

Research interests

RESEARCHINTERESTSAND EXPERIENCE

During my career I have been working ondifferent projects including: 1) The development of immunomodulatory cancervaccines to treat Acute Myeloid Leukaemia (AML) (Clinical Immunology),2)Investigation of the role of endogenous retroviruses in Multiple Sclerosis(MS)(Clinical Virology) and 3) Revealing the signalling of orexinergic receptorstowards cell fate determination(Neuroscience).

Since January 2006 I have been workingat Professor Oliver Hanemann’s laboratory (Plymouth University Peninsula Schoolsof Medicine and Dentistry, The Institute of Translational and StratifiedMedicine). My work has entered on dissecting the signalling pathways involvedin the development of Merlin-deficient tumours in order to find specific andeffective therapeutic targets. I have successfully achieved external fundingfrom six different charities where I was lead or singleapplicant. Additionally, I have published ten first authored papers, onepaper as Director of studies and one book chapter and one invited article inNature Reviews Neurology. I have also contributed to six other papers publishedby my colleagues. 

Ph.D. studentssupervision: three PhD students- first supervisor (DoS, onecompleted2018), 1- co-supervisor (DoS, completed 2018), 1- co-supervisor. 

Our research team havereceived an award from Neurofibromatosis (NF) Advocature in recognition of ourresearch and continued commitment to NF2. Additionally, my work within theNF2 field contributed to phase 0 clinical trials at our unit in collaboration withManchester Hospital. My main goal is to find a good drug treatment for schwannomasand other Merlin-deficient tumours.

Other research

PREVIOUS PROJECTS

 

2011-2013

1.   p53/mouse double minute 2homolog complex deregulation in Merlin-deficient tumours

This project involved investigation of the role of p53 deregulation inschwannoma development and targeting pathways involved in p53 degradation. Inthis project I was first author.

2.  Gas6/Axl-family receptors in schwannoma pathological proliferation, adhesionand survival

In this project we have investigated the role of Axl receptor inschwannoma pathological proliferation, cell-matrix adhesion and survival. Inthis project I was first and corresponding author.

 

2010-2012

1.  The role of insulin-like growth factors (IGF1/2) signalling inMerlin-deficient human schwannomas

2.  Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannomaproliferation, adhesion and survival

In these studies we have demonstrated that IGF1/2 and IGFBP-1 arereleased from schwannoma cells and IGF-I receptor overexpressed leading toincreased schwannoma proliferation and cell-matrix adhesion. In these projectsI was first author.

 

2010-2011

Nilotinib alone or incombination with selumetinib is a drug candidate for neurofibromatosis type 2

In this project we have tested the therapeutic effectiveness of a PDGFRinhibitor Nilotinib and a MEK1/2 inhibitor selumetinib (AZD6244), in humanschwannoma in vitro model. In these projects I was firstauthor.

 

2009-2010

ErbB/HER receptoractivation and preclinical efficacy of lapatinib in vestibular schwannoma

This project was in collaboration with Dr Karajannis (USA) to testEGFR/HER inhibitor Lapatinib in human schwannoma in vitro model. In theseprojects I shared first authorship.

 

2008-2009

Targeting ERK1/2 activationand proliferation in human primary schwannoma cells with MEK1/2 inhibitorAZD6244

In this study we have tested the therapeutic effectiveness of a MEK1/2inhibitor AZD6244, in human schwannoma in vitro model. Inthese projects I was first author.

2007-2008

Dissecting and targetingthe growth factor-dependent and growth factor-independent extracellularsignal-regulated kinase pathway in human schwannoma

Here we demonstrated that PDGFRβ is strongly overexpressedin schwannoma cells leading to increased schwannoma proliferation. We have alsosuccessfully tested a PDGFR/Raf inhibitor Sorafenib. In these projects I wasfirst author.

 

1999-2005

PhD project                                                                                          

Orexin Receptors inRecombinant CHO Cells. Signaling to Short- and Long Term Cells responses

The aim of this study was to investigate the mechanisms of orexinreceptor coupling to the cascades regulating cell fate and also the assessmentof the molecular determinants involved in orexin peptide-orexin receptorinteraction.

 

1997-1998

Research project

Endogenous retroviruses inneurodegenerative diseases

This project focused on the investigation of the expression of theendogenous retrovirus (ERV9)-related proteins in peripheral blood cells andpresence in sera from multiple sclerosis (MS) patients.

 

1996-1997

MSc research project

Immunomodulatory-and-cytokinegene-cancer therapy

The aim of this was to design cancer vaccines to treat leukemia andlymphoma. The vaccines would be implemented in both immunotherapy and genetherapy. For immunotherapy, human blood monocytes were separated anddifferentiated into dendritic cells for antigen presentation and activation ofcellular immunity. For cytokine gene therapy, genes for various cytokines weretransferred into acute myeloid leukemia (AML) cells via retrovirus- andadenovirus based vectors.

 

2011-2019

Clinical Research

I was involved in phase 0 clinical trials testing Sorafenib inNeurofibromatosis type 2 (NF2) patients. I perform tests on tumour tissue andblood samples from patients to look for the effect of these drugs on signallingpathways known to be involved in the development of Merlin-deficient tumours.

 

 


Research degrees awarded to supervised students

Supervisor ofPh.D. students: 3- first supervisor (DoS), 1- co-supervisor (DoS), 1- co-supervisor.

Grants & contracts

RESEARCHGRANTS

2018  AnimalFree UKcharity 01/08/2018-30/09/2018; ‘Investigating the role of TYRO3, AXL andMERTK(TAM) receptors in Merlin deficient brain tumours; schwannomas andmeningioma’:£1,940.00.

2018 GreatOrmond Street Hospital Children'sCharity Grants: ‘Investigation and targetingcellular prion protein PrPC inNeurofibromatosis type II related tumoursschwannomas, meningiomas and spinalependymomas’. Sylwia Ammoun: lead applicantand DoS; Oliver Hanemannco-applicant. £112,000, two years.

2016 ActionMedicalResearch for children: ‘The role of Endogenous Retroviral proteins inthedevelopment of Merlin-deficient tumours and as potential immunotherapyand/ordrug targets’. Sylwia Ammoun: lead applicant and DoS, RobertBelshaw:co-applicant. September 2016-September 2018. Consumables£65,061.                                  

2015 InternalPhDstipend: ‘Endogenous Retroviral proteins as potential drug targets forMerlin-deficienttumours and their role in tumour development’.Sylwia Ammoun:lead applicant andDoS, Robert Belshaw: co-applicant. November 2016-November 2019. Student’s stipend, £61,000.

2014   Action onHearing Loss Flexi grant, ‘Endogenous Retroviral proteins aspotentialimmunotherapy and/or drug targets for Merlin-deficient tumourstreatment andtheir role in vestibular neuroma development’. Sylwia Ammoun:leadapplicant and DoS, Robert Belshaw: co-applicant. November 2014-April2014.Consumables £4697.

2014   TheLaura Crane Youth Cancer Trust grant, ‘The role of prion proteinsinMerlin-deficient tumours’. Sylwia Ammon: principal applicant and DoS.October2014-October 2016. Consumables £24,000.

2013 InternalPhDstipend. ‘The role of cellular prion proteins in schwannoma and otherMerlin-deficient tumours’. Sylwia Ammoun: Principal applicant and DoS.October2013-October 2016.Student’s stipend £61,000.

2009 NorthcottDevon Medical Foundation project grant, single applicant. Therole of Insulinlike growth factors in schwannoma development.£5,000.


Research groups

Key publications are highlighted

Journals
Articles
Hanemann CO, Ammoun S, Evans G, Hilton DA, Streeter A & Hayward C 2019 'Phase 0 trial investigating the intra-tumoural concentration and activity of Sorafenib in Neurofibromatosis type 2' Journal of Neurology, Neurosurgery and Psychiatry PEARL
Stepanova DS, Semenova G, Kuo Y-M, Andrews AJ, Ammoun S, Hanemann CO & Chernoff J 2017 'An essential role for the tumor suppressor Merlin in regulating fatty acid synthesis' Cancer Research Author Site , DOI PEARL
Provenzano L, Ryan Y, Hilton DA, Lyons-Rimmer J, Dave F, Maze EA, Adams CL, Rigby-Jones R, Ammoun S 2017 'Cellular prion protein (PrPC) in the development of Merlin-deficient tumours' Oncogene , DOI PEARL
Zhou L, Lyons-Rimmer J, Ammoun S, Müller J, Lasonder E, Sharma V, Ercolano E, Hilton D, Taiwo I 2015 'The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors' Oncogene 35, (26) 3443-3453 , DOI PEARL
Ammoun S, Provenzano L, Zhou L, Schmid MC & Hanemann CO 2014 'IDENTIFICATION AND TARGETING PATHWAYS INVOLVED IN THE DEVELOPMENT OF MERLIN-DEFICIENT TUMOURS' ANTICANCER RESEARCH 34, (10) 5805-5805 Author Site
Provenzano L, Ammoun S & Hanemann CO 2014 'THE ROLE OF CELLULAR PRION PROTEIN IN SCHWANNOMA AND OTHER MERLIN-DEFICIENT TUMOURS' ANTICANCER RESEARCH 34, (10) 6123-6123 Author Site
Ammoun S, Schmid MC, Zhou L, Hilton DA, Barczyk M & Hanemann CO 2014 'The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours' Mol Oncol 9, (1) 236-248 Author Site , DOI
Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW 2014 'CTF Meeting 2012: Translation of the Basic Understanding of the Biology and Genetics of NF1, NF2, and Schwannomatosis Toward the Development of Effective Therapies' AMERICAN JOURNAL OF MEDICAL GENETICS PART A 164, (3) 563-578 Author Site , DOI
Shivane A, Parkinson DB, Ammoun S & Hanemann CO 2013 'Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas' HISTOPATHOLOGY 62, (4) 651-656 Author Site , DOI
Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, Hafizi S & Hanemann CO 2013 'Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival' Oncogene 33, (3) 336-346 Author Site , DOI PEARL
Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C & Hanemann CO 2012 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas' Glia 60, (11) 1721-1733 Author Site , DOI PEARL
Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, Perks CM & Hanemann CO 2012 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C, Hanemann CO. Glia. 2012 Nov;60(11):1721-33. doi: 10.1002/glia.22391. Epub 2012 Jul 20' Glia
Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, Perks CM & Hanemann CO 2012 'Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival' Oncogene 31, (13) 1710-1722 Author Site , DOI
Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA & Hanemann CO 2011 'Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways' Neoplasia 13, (12) 1101-1112 Author Site
Ammoun S, Schmid MC, Triner J, Manley P & Hanemann CO 2011 'Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2' Neuro Oncol 13, (7) 759-766 Author Site , DOI
Ammoun S & Hanemann CO 2011 'Emerging therapeutic targets in schwannomas and other merlin-deficient tumors' Nat Rev Neurol 7, (7) 392-399 Author Site , DOI
Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO & Karajannis MA 2010 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro Oncol 12, (8) 834-843 Author Site , DOI
Ammoun S, Ristic N, Matthies C, Hilton DA & Hanemann CO 2010 'Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244' Neurobiol Dis 37, (1) 141-146 Author Site , DOI
Flaiz C, Chernoff J, Ammoun S, Peterson JR & Hanemann CO 2009 'PAK kinase regulates Rac GTPase and is a potential target in human schwannomas' Exp Neurol 218, (1) 137-144 Author Site , DOI
Ammoun S 2009 'Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. Flaiz, Christine; Ammoun, Sylwia; Biebl, Anja; Hanemann, C. Oliver. Brain Pathology, Volume 19, Number 1, January 2009, pp. 27-38(12)'
Flaiz C, Ammoun S, Biebl A & Hanemann CO 2009 'Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma' Brain Pathol 19, (1) 27-38 Author Site , DOI
Ammoun S, Flaiz C, Ristic N, Schuldt J & Hanemann CO 2008 'Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma' Cancer Res 68, (13) 5236-5245 Author Site , DOI
Ammoun S & Hanemann O 2007 'Strong and long-lasting activation of ERK in human schwannoma cells' Neuropathology and Applied Neurobiology 33, (2) 258-259
Ammoun S 2006 'OX1 orexin receptors activate extracellular signal-regulated kinase in Chinese hamster ovary cells via multiple mechanisms: the role of Ca2+ influx in OX1 receptor signaling. Ammoun S, Johansson L, Ekholm ME, Holmqvist T, Danis AS, Korhonen L, Sergeeva OA, Haas HL, Akerman KE, Kukkonen JP. Mol Endocrinol. 2006 Jan;20(1):80-99. Epub 2005 Sep 1'
Ammoun S 2006 'G-protein-coupled OX1 orexin/hcrtr-1 hypocretin receptors induce caspase-dependent and -independent cell death through p38 mitogen-/stress-activated protein kinase. Ammoun S, Lindholm D, Wootz H, Akerman KE, Kukkonen JP. J Biol Chem. 2006 Jan 13;281(2):834-42. Epub 2005 Nov 10'
Ammoun S, Johansson L, Ekholm ME, Holmqvist T, Danis AS, Korhonen L, Sergeeva OA, Haas HL, Åkerman KEO 2006 'OX1Orexin Receptors Activate Extracellular Signal-Regulated Kinase in Chinese Hamster Ovary Cells via Multiple Mechanisms: The Role of Ca2+Influx in OX1Receptor Signaling' Molecular Endocrinology 20, (1) 80-99 , DOI
Ammoun S, Lindholm D, Wootz H, Åkerman KEO & Kukkonen JP 2005 'G-protein-coupled OX1Orexin/hcrtr-1 Hypocretin Receptors Induce Caspase-dependent and -independent Cell Death through p38 Mitogen-/Stress-activated Protein Kinase' Journal of Biological Chemistry 281, (2) 834-842 , DOI
Ammoun S 2005 'OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms. Holmqvist T, Johansson L, Ostman M, Ammoun S, Akerman KE, Kukkonen JP. J Biol Chem. 2005 Feb 25;280(8):6570-9'
Holmqvist T, Johansson L, Östman M, Ammoun S, Åkerman KEO & Kukkonen JP 2004 'OX1Orexin Receptors Couple to Adenylyl Cyclase Regulation via Multiple Mechanisms' Journal of Biological Chemistry 280, (8) 6570-6579 , DOI
Kukkonen JP, Holmqvist T, Ammoun S & Åkerman KEO 2003 'Erratum: Functions of the orexinergic/hypocretinergic system (American Journal of Physiology - Cell Physiology (December 2002) 283 (c1567-c1591))' American Journal of Physiology - Cell Physiology 284, (4 53-4)
Ammoun S 2003 'Distinct Recognition of OX1 and OX2 Receptors by Orexin Peptides' Journal of Pharmacology and Experimental Therapeutics 305, (2) 507-514 , DOI
Ammoun S 2003 'Distinct recognition of OX1 and OX2 receptors by orexin peptides. Ammoun S, Holmqvist T, Shariatmadari R, Oonk HB, Detheux M, Parmentier M, Akerman KE, Kukkonen JP. J Pharmacol Exp Ther. 2003 May;305(2):507-14. Epub 2003 Jan 24'
Ammoun S 2002 'Functions of the orexinergic/hypocretinergic system. Kukkonen JP, Holmqvist T, Ammoun S, Akerman KE. Am J Physiol Cell Physiol. 2002 Dec;283(6):C1567-91. Review. Erratum in: Am J Physiol Cell Physiol. 2003 Apr;284(4)'
Kukkonen JP, Holmqvist T, Ammoun S & Åkerman KEO 2002 'Functions of the orexinergic/hypocretinergic system' American Journal of Physiology-Cell Physiology 283, (6) C1567-C1591 , DOI
Nasman J, Kukkonen JP, Ammoun S & Akerman KEO 2001 'Role of G-protein availability in differential signaling by alpha 2-adrenoceptors 1 1Abbreviations: α2-AR, α2-adrenergic receptor; AC, adenylyl cyclase; GTPγS, guanosine 5′-O-(3-thiotriphosphate); IBMX, 3-isobutyl-1-methyl-xanthine; UK14,304, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine' Biochemical Pharmacology 62, (7) 913-922 , DOI
Ammoun S 2001 'Role of G-protein availability in differential signaling by alpha 2-adrenoceptors. Nasman J, Kukkonen JP, Ammoun S, Akerman KE. Biochem Pharmacol. 2001 Oct 1;62(7):913-22'
Ammoun S 2000 'Recombinant expression of a selective blocker of M(1) muscarinic receptors. Näsman J, Jolkkonen M, Ammoun S, Karlsson E, Akerman KE. Biochem Biophys Res Commun. 2000 May 10;271(2):435-9'
Näsman J, Jolkkonen M, Ammoun S, Karlsson E & Åkerman KEO 2000 'Recombinant Expression of a Selective Blocker of M1 Muscarinic Receptors' Biochemical and Biophysical Research Communications 271, (2) 435-439 , DOI
Olsson P, Ryberg B, Awad R, Ammoun S, Yin H, Hjalmarsson S & Blomberg J 1999 'Retroviral RNA Related to ERV9/MSRV in a Human Serum: A New Sequence Variant' AIDS Research and Human Retroviruses 15, (6) 591-593 , DOI
Ammoun S 1999 'Retroviral RNA related to ERV9/MSRV in a human serum: a new sequence variant. Olsson P, Ryberg B, Awad R, Ammoun S, Yin H, Hjalmarsson S, Blomberg J. AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):591-3'
Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO & Karajannis MA 0 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro-oncology Publisher Site , DOI PEARL
Chapters
Publisher BS 2012 'Receptor Tyrosine Kinases in Human Schwannoma' Angiogenesis & Therapeutic Targets In Cancer BENTHAM SCIENCE PUBLISHERS 90-98 , DOI
Conference Papers
Maze E, Reeves S, Hilton D, Provenzano L, Belshaw R & Ammoun S 2016 'Abstract 4627: The role of human endogenous retroviral proteins in the development of Merlin-deficient tumors and as potential drug targets' American Association for Cancer Research (AACR) 4627-4627 , DOI
Hanemann CO, Zhou L, Ammoun S, Lasonder E, Sharma V, Muller J & Ercolano E 2015 'Abstract 704: Scaffold protein KSR1 is negatively regulated by merlin and promotes tumor development in merlin deficient tumors' American Association for Cancer Research (AACR) 704-704 , DOI
Hanemann CO, Ammoun S, Schmid MC & Zhou L 2014 'Abstract 2609: The role of focal adhesion kinase (FAK), PI3K/AKT and p53/mouse double minute 2 homologue (MDM2) complex in the pathobiology of Merlin-deficient tumors' American Association for Cancer Research (AACR) 2609-2609 , DOI
Hilton D, Shivane A, Kirk L, Ammoun S & Hanemann CO 2014 'Growth factor signaling pathway activation in meningiomas' 101-101
Hilton DA, Shivane A, Turner L, Ammoun S & Hanemann O 2013 'Activation of multiple signalling pathways in meningiomas is unrelated to NF2 gene status' 35-35
Shivane A, Parkinson DB, Ammoun S & Hanemann CO 2012 'Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas' Wiley 651-656 , DOI
Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk M & Hanemann CO 2012 'MERLIN DEFICIENT HUMAN TUMOURS SHOW LOSS OF CONTACT INHIBITION, ACTIVATION OF WNT/beta-CATENIN SIGNALING LINKED TO THE PDGFR/SRC AND RAC/PAK PATHWAYS' 5-6
Ammoun S, Zhou L, Barczyk M, Hilton D, Hafizi S & Hanemann CO 2011 'GAS6/AXL-FAMILY RECEPTORS IN SCHWANNOMA PATHOLOGICAL PROLIFERATION, ADHESION AND SURVIVAL' 1-1
Schmid MC, Zhou L, Ammoun S & Hanemann CO 2010 'Targeting focal adhesion kinase (FAK) in primary human schwannoma' 42-42 , DOI
Hanemann CO, Ammoun S, Schmid MC, Ristic N, Ercolano E & Zhou L 2010 'IGF/IGFBP SIGNALING IN MERLIN-DEFICIENT TUMORS' 22-22
Hanemann CO & Ammoun S 2009 'MERLIN'S TUMOURS: FROM BENCH TO BEDSIDE' , DOI
Mackay L, Higgins S, Abderrahim A, Mistry P, Ammoun S, Whitaker G, Akinwunmi J, Hanneman CO & Pilkington GJ 2008 'IGF-BP1/2 expression in histological sections, biopsy-derived cell cultures and cyst fluids from nervous system neoplasms' 21-21
Ammoun S & Hanemann O 2007 'Strong and long-lasting activation of ERK in human schwannoma cells' 258-259